Status:
UNKNOWN
Presynaptic Imaging in Major Depressive Episodes After COVID-19
Lead Sponsor:
Centre for Addiction and Mental Health
Conditions:
Long COVID
Major Depressive Disorder
Eligibility:
All Genders
18-75 years
Brief Summary
The goal of this observational study focuses on understanding and addressing a subset of persistent neuropsychiatric symptoms occurring within 3 months after mild to moderate COVID-19 infection (COVID...
Detailed Description
Participants will undergo two positron emission tomography (PET) scans, one \[11C\]DTBZ scan (for vesicular monoamine transporter 2 (VMAT2) and one \[18F\]SDM8 scan (for synaptic vesicle glycoprotein ...
Eligibility Criteria
Inclusion
- New onset MDE within 3 months after mild or moderate COVID-19, with MDE verified by the research version SCID for DSM 5. See "Positive COVID-19 diagnosis" listed after inclusion/exclusion criteria for a description of how this is determined.
- Age 18 to 75.
- Good general physical health with no active medical conditions based on self-report (except migraine or PASC).
Exclusion
- Use of antidepressants in the previous month (6 weeks for fluoxetine).
- Use of stimulant medication affecting dopamine release in the previous month
- Use of antipsychotics in the previous month
- History of neurological disease (except migraine, and PASC) based on self-report
- Use of medications or herbal products or natural health products with central nervous system effects in past 2 weeks based on self-report
- Presence of cigarette smoking in the past two months, based on self-report
- Lifetime diagnosis of severe Substance or Alcohol Use Disorder, or diagnosis of mild to moderate Substance or Alcohol Use Disorder in the past two years, based on self-report and verified by the Research Version of Structured Clinical Interview for Diagnostic and Statistical Manual-5 (SCID-5-RV)
- Use of recreational drugs, including marijuana, in the past two months, based on self-report and verified by the Research Version of Structured Clinical Interview for Diagnostic and Statistical Manual-5 (SCID-5-RV)
- Positive urine drug or cotinine screen at any timepoint during the study
- History of psychotic symptoms secondary to schizophrenia, schizophreniform, bipolar disorder, or brief psychotic disorder prior to COVID-19, based on self-report and verified by the Research Version of Structured Clinical Interview for Diagnostic and Statistical Manual-5 (SCID-5-RV)
- Currently pregnant, based on self-report or positive pregnancy test at any timepoint during the study, in females (in our PET Centre females up to 65 years of age are given a urine pregnancy test prior to every PET scan)
- Breastfeeding (for females)
- Current disorders of coagulation, blood or ongoing use of anticoagulant medication, based on self-report
- Claustrophobia, based on self-report
- Weight over 400lbs and height over 7ft (requirements for fitting in the scanners and hospital gowns)
- Presence of metal implant, object or electrical devices that are contraindicated for MRI, based on self-report
- Severe allergic reaction to alcohol
Key Trial Info
Start Date :
August 22 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 10 2025
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT06086366
Start Date
August 22 2023
End Date
September 10 2025
Last Update
October 17 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre for Addiction and Mental Health
Toronto, Ontario, Canada